The phase III ADAURA trial conclusively demonstrated that the administration of adjuvant osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was associated with enhanced postoperative outcomes in patients with pathological stage IB–IIIA EGFR-mutated lung adenocarcinoma (1, 2). This evidence concerns the gene EGFR and lung adenocarcinoma.